Changeflow GovPing Government & Legislation National Health (Efficient Funding of Chemother...
Priority review Rule Added Final

National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024

Favicon for www.legislation.gov.au AU Federal Legislative Instruments (7-day)
Published
Detected
Email

Summary

The Australian Department of Health, Disability and Ageing has promulgated the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024 under the National Health Act 1953. This legislative instrument establishes the framework for prescribing, supplying, and funding chemotherapy drugs and related pharmaceutical benefits through the PBS. The arrangement applies to approved pharmacists, approved medical practitioners, approved hospital authorities, and TGA-licensed compounders involved in chemotherapy treatment delivery.

Published by DoHDA on legislation.gov.au . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This legislative instrument establishes a comprehensive special arrangement for the efficient funding of chemotherapy under Australia's Pharmaceutical Benefits Scheme. The instrument defines authorized prescribers, eligible patients, and sets out rules for prescribing doses of chemotherapy drugs and related pharmaceutical benefits, including maximum amounts, quantities, and repeat allowances. It also governs the supply chain through approved pharmacists, approved medical practitioners, approved hospital authorities, and TGA-licensed compounders, with specific payment provisions for each.

Healthcare providers including hospitals, oncologists, pharmacists, and TGA-licensed compounders must comply with the procedural requirements for chemotherapy prescriptions, supply chains, and claims processing under this arrangement. The instrument modifies standard PBS rules for chemotherapy-specific circumstances, including modified rules for electronic medication chart prescriptions and variation procedures for prescribed doses.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

- Interactions

National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024

In force Administered by
- Department of Health, Disability and Ageing
This item is authorised by the following title:


View document Legislative instrument Filter active Table of contents
- Part 1—Preliminary
- 1 Name
- 3 Authority
- 4 Simplified outline
- 5 Definitions
- 6 Definition of authorised prescriber
- 7 Definition of eligible patient
- 8 Application of Act and instruments in relation to special arrangement supplies to patients receiving treatment from hospitals
- 9 Application of Act and instruments in relation to chemotherapy prescriptions and special arrangement supplies of doses of chemotherapy drugs
- Part 2—Special arrangement supplies
- Division 1—Preliminary
- 10 Definition of special arrangement supply
- Division 2—Prescribing doses of chemotherapy drugs and related pharmaceutical benefits
- 11 Prescribing chemotherapy drugs
- 12 Prescription circumstances—general
- 13 Prescription circumstances—authority required procedures
- 14 Maximum amount—chemotherapy drugs
- 14A Prescribing amounts of active ingredients in dose of chemotherapy drug
- 15 Maximum quantity (number of units)—related pharmaceutical benefits
- 16 Maximum number of repeats—chemotherapy drugs
- 17 Maximum number of repeats—related pharmaceutical benefits
- 18 Variation of maximum amount or quantity or maximum number of repeats
- 19 Writing chemotherapy prescriptions that are not medication chart prescriptions
- 20 Writing medication chart prescriptions
- 21 Direction to vary prescribed dose of chemotherapy drug
- Division 3—Supplying doses of chemotherapy drugs and related pharmaceutical benefits
- 22 Entitlement to receive special arrangement supplies
- 23 Special arrangement supplies of doses of chemotherapy drugs
- 24 Rules not applicable to special arrangement supplies of chemotherapy drugs
- 25 Modified rules for special arrangement supplies on the basis of an electronic medication chart prescription
- Part 3—Claims, information and payment
- Division 1—Claims for payment and giving information
- 26 Modified requirements for claims or giving information
- Division 2—Payment of claims
- 27 Payment of approved pharmacists and approved medical practitioners for supplies of doses of chemotherapy drugs
- 28 Payment of approved hospital authorities for supplies
- 29 No separate entitlement to payment for supplies of diluent
- 30 Payment of TGA-licensed compounders
- Division 3—Dispensed price for dose of chemotherapy drug
- 31 Dispensed price for doses supplied by approved pharmacists and approved medical practitioners
- 32 Mark-up for a chemotherapy pharmaceutical benefit
- 33 Dispensed price if dose is supplied by approved private hospital authority
- 34 Dispensed price if dose is supplied by approved public hospital authority
- Division 4—Dispensed price for related pharmaceutical benefit
- 35 Dispensed price for supply of related pharmaceutical benefit
- Part 4—Patient contributions
- 36 Supplies of doses of chemotherapy drugs by approved pharmacists and approved medical practitioners
- 37 Supplies of doses of chemotherapy drugs by approved hospital authorities
- 38 Supplies of related pharmaceutical benefits—special patient contribution
- 39 Application of safety net provisions
- Part 5—Supply to CTG registered patients by CTG suppliers
- 40 Application of the CTG Special Arrangement—original special arrangement supply of a dose of a chemotherapy drug
- 41 Application of the CTG Special Arrangement—special arrangement supply of a related pharmaceutical benefit
- Schedule 1—Chemotherapy pharmaceutical benefits and chemotherapy drugs
- Part 1—Chemotherapy pharmaceutical benefits
- 1 Chemotherapy pharmaceutical drugs and chemotherapy pharmaceutical benefits
- Part 2—Maximum amounts and number of repeats for chemotherapy drugs
- 2 Maximum amounts and number of repeats
- Schedule 2—Related pharmaceutical benefits
- 1 Related pharmaceutical benefits and related information
- Schedule 3—Circumstances, purposes and variations
- Part 1—Circumstances and purposes
- 1 Circumstances and purposes
- Part 2—Variation rules
- 2 Variation rules
- Endnotes
- Endnote 1—About the endnotes
- Endnote 2—Abbreviation key
- Endnote 3—Legislation history
- Endnote 4—Amendment history

Named provisions

Special arrangement supplies Prescribing chemotherapy drugs Supplying doses of chemotherapy drugs Payment of claims

Get daily alerts for AU Federal Legislative Instruments (7-day)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from DoHDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
DoHDA
Published
April 1st, 2024
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
F2024L00405

Who this affects

Applies to
Healthcare providers Pharmaceutical companies
Industry sector
6221 Hospitals & Health Systems
Activity scope
Chemotherapy drug prescribing Pharmaceutical benefits supply Healthcare payment claims
Geographic scope
Australia AU

Taxonomy

Primary area
Healthcare
Operational domain
Healthcare
Compliance frameworks
GxP
Topics
Pharmaceuticals

Get alerts for this source

We'll email you when AU Federal Legislative Instruments (7-day) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!